Request Sample
Request Methodology
Description
Follicular Lymphoma Treatment Market
Follicular lymphoma is the second most common indolent non-Hodgkin’s lymphoma and it develops when the body makes abnormal B-lymphocytes in lymph nodes. The symptoms associated with follicular lymphoma include enlargement of lymph nodes in neck, abdomen, and groin, weight loss, difficulties in breathing, fatigue, and night sweats. Follicular lymphoma is diagnosed by biopsy, blood tests, and X-rays among others. Follicular lymphoma can be treated with chemotherapy, radiation therapy, targeted therapy, and stem cell transplant.
Market Dynamics:
Rise in prevalence of follicular lymphoma, family history of blood disorders, increase in R&D activities for the innovation of newer drugs, and technological advancements in disease diagnosis are anticipated to fuel the follicular lymphoma treatment market. Moreover, promising pipeline products, innovation of newer therapies such as monoclonal antibodies, and government initiations for the cancer management are expected to boost the market over the forecast period. However, stringent regulatory policies for drug approval, the high cost of treatment, and adverse effects associated with the treatment are expected to hamper the growth of follicular lymphoma treatment market over the forecast years.
Market Scope:
Follicular lymphoma treatment market is segmented on the basis of treatment type, route of administration, end user, and region
Based on the treatment type, the market is segmented into the following:
- Chemotherapy
- Alkylating Agents
- Nucleoside Analogues
- Anthracycline Derivatives
- Others
- Radiotherapy
- Monoclonal Antibodies
- Stem Cell Transplantation
Based on the route of administration, the market is segmented into the following:
- Oral
- Parenteral
- Others
Based on the end user, the market is segmented into the following:
- Hospitals
- Retail Pharmacies
- Oncology Centers
- Academic Research Institutes
Based on region, the market is segmented into the following:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Market Summary:
Follicular lymphoma treatment market is poised to grow at significant rate owing to increase in the R&D activities for the innovation newer therapies and drugs. Most of the international players are actively involved in the development of newer products. For instance, in December 2015, Novartis announced phase IIa study results of CTL019 used in the treatment of certain types of lymphoma including follicular lymphoma. Moreover, rising adoption of monoclonal antibodies for targeted therapies propels the follicular lymphoma treatment market. Furthermore, acquisitions and mergers, collaborations, product approvals, and product launchings are the strategies followed by the market players for gaining larger revenue share in follicular lymphoma treatment market. For instance, in February 2017, Health Canada approved Roche’s Gazyva (Obinutuzumab) for patients with previously treated follicular lymphoma. In addition, in August 2017, Epizyme, Inc. and US Oncology Research are collaborated to identify the non-Hodgkin lymphoma patients with EZH2 mutations and eligible patients are directed to ongoing phase 2 clinical trial of Tazemetostast in diffuse large B-cell lymphoma and follicular lymphoma.
Regional Analysis:
Geographically, global follicular lymphoma treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America follicular lymphoma treatment market is poised to grow at notable rate due to increase in the prevalence of follicular lymphoma (according to American Cancer Society, approximately 20% of follicular lymphoma cases observed among all types lymphoma patients), increase in R&D activities for the innovation of newer drugs, an increase in healthcare expenditure in the region. Europe follicular lymphoma treatment market is expected to grow significantly due to the adoption of newer therapies, sophisticated healthcare infrastructure, an increase in the prevalence of follicular lymphoma due to change in lifestyle in the region. Asia Pacific follicular lymphoma treatment market has a lucrative growth owing to the large patient pool, increase in awareness about lymphoma treatment, and government initiations for the prevention of cancer are expected to fuel the market in the region. Latin America follicular lymphoma treatment market expected to grow at moderate rate due to the expansion of business into the region by market players, adoption of newer drugs, and economic growth are bolster the market. Middle East and Africa follicular lymphoma treatment market have a growth attributed to rising in awareness about lymphoma treatment, increase in the prevalence of follicular lymphoma, and growing per capita income.
Major Key Players:
- Hoffmann La Roche Ltd. (Switzerland)
- Novartis AG (Switzerland)
- GlaxoSmithKline plc (U.K.)
- Merck & Co. Inc. (U.S.)
- AbbVie, Inc. (U.S.)
- Bayer AG (Germany)
- Epizyme Inc. (U.S.)
- Bristol Myers Squibb (U.S.)
- Johnson and Johnson Services Inc. (U.S.)
Notable Market Developments:
- In October 2017, U.S. Food and Drug Administration approved Bayer AG’s Aliqopa (Copanlisib) for the treatment of follicular lymphoma
Key Features of the Report:
- The report provides granular level information about the market size, regional market share, historic market (2015 to 2019) and forecast (2020 to 2026)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Location
GEOGRAPHY
